A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

NCT06434610 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer

Interventions

DRUG: B013
DRUG: Paclitaxel
DRUG: Placebo

Sponsor

Shanghai Jiaolian Drug Research and Development Co., Ltd

Collaborators

[object Object]